NewAmsterdam Pharma provided a corporate update, highlighting its achievements in 2024, including compelling data from three pivotal Phase 3 trials: BROOKLYN, TANDEM, and BROADWAY. The company reported an unaudited cash balance of $835 million at year-end 2024, providing substantial financial runway.
For 2025, the company expects additional data from its Phase 3 trials to be presented throughout the year, supporting global regulatory filings. An EMA submission by its partner Menarini is anticipated in the second half of 2025, marking a key regulatory milestone.
NewAmsterdam Pharma is also focusing on commercial readiness, including establishing manufacturing capacity and building inventory. Data from the Phase 2 VINCENT trial, exploring obicetrapib's effect on Lp(a), is expected by the second half of 2025, potentially expanding the drug's profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.